Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Qelbree with Psychostimulants in Pediatric ADHD
NCT04786990Phase 4Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Jul 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of viloxazine in attention deficit hyperactivity disorder (ADHD), sponsored by Supernus Pharmaceuticals, Inc.. Started Jul 2021; status: completed.
02
Drugs
viloxazine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04786990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04786990.